Suppr超能文献

孕早期母体甲状腺功能减退与婴儿结构性先天性畸形

Maternal hypothyroidism in early pregnancy and infant structural congenital malformations.

作者信息

Källén Bengt, Norstedt Wikner Birgitta

机构信息

Tornblad Institute, Lund University, Biskopsgatan 7, 223 62 Lund, Sweden.

National Board of Health and Welfare, 10630 Stockholm, Sweden ; Karolinska Institutet, Department of Medicine, Centre for Pharmacoepidemiology, 17176 Stockholm, Sweden.

出版信息

J Thyroid Res. 2014;2014:160780. doi: 10.1155/2014/160780. Epub 2014 Mar 12.

Abstract

Background. The question is debated on whether maternal hypothyroidism or use of thyroxin in early pregnancy affects the risk for infant congenital malformations. Objectives. To expand the previously published study on maternal thyroxin use in early pregnancy and the risk for congenital malformations. Methods. Data from the Swedish Medical Birth Register were used for the years 1996-2011 and infant malformations were identified from national health registers. Women with preexisting diabetes or reporting the use of thyreostatics, anticonvulsants, or antihypertensives were excluded from analysis. Risk estimates were made as odds ratios (ORs) or risk ratios (RRs) after adjustment for year of delivery, maternal age, parity, smoking, and body mass index. Results. Among 23 259 infants whose mothers in early pregnancy used thyroxin, 730 had a major malformation; among all 1 567 736 infants, 48012 had such malformations. The adjusted OR was 1.06 (95% CI 0.98-1.14). For anal atresia the RR was 1.85 (95% CI 1.00-1.85) and for choanal atresia 3.14 (95% CI 1.26-6.47). The risk of some other malformations was also increased but statistical significance was not reached. Conclusions. Treated maternal hypothyroidism may be a weak risk factor for infant congenital malformations but an association with a few rare conditions is possible.

摘要

背景。关于孕期甲状腺功能减退或孕早期使用甲状腺素是否会影响婴儿先天性畸形的风险存在争议。目的。扩展先前发表的关于孕早期母亲使用甲状腺素与先天性畸形风险的研究。方法。使用瑞典医学出生登记处1996 - 2011年的数据,并从国家健康登记处识别婴儿畸形情况。分析中排除了患有糖尿病或报告使用抗甲状腺药物、抗惊厥药物或抗高血压药物的女性。在对分娩年份、母亲年龄、产次、吸烟情况和体重指数进行调整后,风险估计以比值比(OR)或风险比(RR)表示。结果。在23259名母亲在孕早期使用甲状腺素的婴儿中,730名有严重畸形;在所有1567736名婴儿中,48012名有此类畸形。调整后的OR为1.06(95%可信区间0.98 - 1.14)。肛门闭锁的RR为1.85(95%可信区间1.00 - 1.85),后鼻孔闭锁的RR为3.14(95%可信区间1.26 - 6.47)。其他一些畸形的风险也有所增加,但未达到统计学显著性。结论。经治疗的母亲甲状腺功能减退可能是婴儿先天性畸形的一个较弱风险因素,但可能与少数罕见情况有关。

相似文献

3
Use of ondansetron during pregnancy and congenital malformations in the infant.孕期使用昂丹司琼与婴儿先天性畸形
Reprod Toxicol. 2014 Dec;50:134-7. doi: 10.1016/j.reprotox.2014.10.017. Epub 2014 Oct 31.

引用本文的文献

3
Antithyroid drugs and birth defects.抗甲状腺药物与出生缺陷。
Thyroid Res. 2020 Jun 27;13:11. doi: 10.1186/s13044-020-00085-8. eCollection 2020.
7
Craniosynostosis and risk factors related to thyroid dysfunction.颅缝早闭与甲状腺功能障碍相关的危险因素。
Am J Med Genet A. 2015 Apr;167A(4):701-7. doi: 10.1002/ajmg.a.36953. Epub 2015 Feb 5.

本文引用的文献

4
[Thyreotic embryopathy].
Arch Kinderheilkd. 1956;153(1-2):123-41.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验